Tocilizumab + Prednisone

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Giant Cell Arteritis

Conditions

Giant Cell Arteritis

Trial Timeline

Nov 28, 2018 → Dec 29, 2021

NCT ID

NCT03726749

About Tocilizumab + Prednisone

Tocilizumab + Prednisone is a approved stage product being developed by Roche for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03726749. Target conditions include Giant Cell Arteritis.

What happened to similar drugs?

4 of 13 similar drugs in Giant Cell Arteritis were approved

Approved (4) Terminated (3) Active (7)

✅PexidartinibDaiichi SankyoApproved

✅ValganciclovirRocheApproved

✅DenosumabAmgenApproved

✅XGEVA®AmgenApproved

🔄PexidartinibDaiichi SankyoPhase 3

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

🔄Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03726749	Approved	Completed	Nov 28, 2018	Dec 29, 2021	Giant Cell Arteritis

Competing Products

20 competing products in Giant Cell Arteritis

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.	Novartis	Phase 3	40
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Placebo	Roche	Phase 3	44
Tocilizumab	Roche	Phase 3	40
Tocilizumab	Roche	Phase 1	29
Valganciclovir	Roche	Approved	35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]	Amgen	Phase 2	27